Evidence map›Paper›PMID 26280537›Full record

ArticleNature cell biology2015

Secreted and O-GlcNAcylated MIF binds to the human EGF receptor and inhibits its activation.

Yanhua Zheng, Xinjian Li, Xu Qian, Yugang Wang, Jong-Ho Lee, Yan Xia, David H Hawke, Gang Zhang, Jianxin Lyu, Zhimin Lu

Open access · greenAbstract read
In one paragraph

Article in Nature cell biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Research advances of secretory proteins in malignant tumors.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Yanhua ZhengDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Xinjian LiDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Xu QianDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Yugang WangDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Jong-Ho LeeDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Yan XiaDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
David H HawkeDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Gang ZhangDepartment of Surgical Oncology, Affiliated Hospital of Hebei University, Baoding, Hebei 071000, China.
Jianxin LyuKey Laboratory of Laboratory Medicine, Ministry of Education, Zhejiang Provincial Key Laboratory of Medical Genetics, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou 325035, China.
Zhimin LuDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
The University of Texas MD Anderson Cancer Center · USAffiliated Hospital of Hebei University · CNUniversity of Houston · USWenzhou Medical University · CN

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Tropism Enhanced Oncolytic Adenovirus for the Treatment of Brain TumorsP50CA127001 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Juan Fueyo · 2008 to 2026
$41.2M
The Role of b-catenin in EGFR-Related Tumor DevelopmentR01CA109035 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LU, ZHIMIN · 2005 to 2016
$2.7M
The Mechanisms of PKM2-Regulated Gene Expression in Tumor Development.R01CA169603 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LU, ZHIMIN · 2013 to 2017
$1.7M
Deciphering the role of Cdc25A in cancer metabolism.R01NS089754 · NINDS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LU, ZHIMIN · 2015 to 2017
$1.1M
Orbitrap Elite High-Resolution Mass Spectrometer for Proteomics and MetabolomicsS10OD012304 · OD · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HAWKE, DAVID H · 2013 to 2013
$877k
NCI NIH HHS 1R0 CA169603NCI NIH HHS 2P50 CA127001NCI NIH HHS 2R01 CA109035NCI NIH HHS CA016672NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA127001NCI NIH HHS R01 CA109035NCI NIH HHS R01 CA169603NIH HHS 1S10 OD012304-01NIH HHS S10 OD012304NINDS NIH HHS 1R01 NS089754NINDS NIH HHS R01 NS089754
6 · The paper itself

Abstract

Activation of epidermal growth factor receptor (EGFR), which occurs in many types of tumour, promotes tumour progression. However, no extracellular antagonist of human EGFR has been identified. We found that human macrophage migration inhibitory factor (MIF) is O-GlcNAcylated at Ser 112/Thr 113 at its carboxy terminus. The naturally secreted and O-GlcNAcylated MIF binds to EGFR, thereby inhibiting the binding of EGF to EGFR and EGF-induced EGFR activation, phosphorylation of ERK and c-Jun, cell invasion, proliferation and brain tumour formation. Activation of EGFR through mutation or its ligand binding enhances the secretion of MMP13, which degrades extracellular MIF, and results in abrogation of the negative regulation of MIF on EGFR. The finding that EGFR activation downregulates its antagonist in the tumour microenvironment represents an important feedforward mechanism for human tumour cells to enhance EGFR signalling and promote tumorigenesis.

Indexed as

AcetylglucosamineAnimalsCell LineCell Line, TumorCell ProliferationEnzyme ActivationEpidermal Growth FactorErbB ReceptorsExtracellular Signal-Regulated MAP KinasesGliomaHumansImmunoblottingJNK Mitogen-Activated Protein KinasesMacrophage Migration-Inhibitory FactorsMatrix Metalloproteinase 13Mice, NudeAcetylglucosamineEGFR protein, humanEpidermal Growth FactorErbB ReceptorsExtracellular Signal-Regulated MAP KinasesJNK Mitogen-Activated Protein KinasesMacrophage Migration-Inhibitory FactorsMatrix Metalloproteinase 13SerineThreonine

Identifiers

PMID26280537
PMCPMC4785887
OpenAlexW1873056941

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.